The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 In the North American patients, the OS HR was 0.70 The HARMONi trial has already demonstrated clinically meaningful and statistically significant progression-free survival (PFS)...
Hence then, the article about ivonescimab plus chemotherapy demonstrates consistent global benefit harmoni data update shows os hr 0 78 nominal p 0 0332 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332 )
Also on site :
- PIN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Pinterest, Inc.
- The Strong Reaction Real-Life Doctors Have To The Pitt, According To Noah Wyle
- Sheena Easton, 66, Is Still a Stunning Redhead Several Years After Leaving the Chaos of Mega-Fame Behind